![]() ![]() That makes it much more like a hospital procedure, like a surgery, than like a drug. With cell therapy you take cells from the patient, you process them, and then you give them back to the patient. This is one of the real phenomenons of bispecifics. ![]() That’s likely because bispecifics more closely resemble traditional products, both in terms of structure and in terms of business models, than gene and cell therapies. That’s not the case for gene and cell therapy. LP: I would say all large pharma is making some effort in bispecifics. SV: Are all large pharma looking at bispecifics or are some still sitting on the fence? It’s taken decades of experimentation, but today we’re definitely seeing results. They’re very stable and predictable, so it can be difficult to force two things into a single molecule. Antibodies have evolved over millions of years. It is a fascinating field because conceptually it’s quite simple, but mechanically it can be quite complex. A third bispecific use is actually tweaking the recognition site of both arms of the antibody such that they bind to either Her2 or Her3. But bispecifics also fit into traditional oncology, such as the work Genentech has done with Her2 and Her3 on the same antibody. In that example, it is defined as immuno-oncology, because it’s bringing the immune cell to the target. One of the bispecifics we refer to is BiTES, which is a method of T-cell engagement, so it's bringing T-cells to the target, such as EGFR. Linda Pullan: The interesting thing about bispecifics is that it can fit into immuno-oncology, but it can also fit into traditional oncology, and increasingly inside autoimmune and inflammation programs. ShareVault: For quite some time we’ve been hearing how hot immuno-oncology and gene and cell therapies are. In advance of the web panel discussion, we sat down with Linda Pullan to learn a little more about bispecifics and what you can expect to learn from the discussion. To find out more about the potential of bispecific antibodies and the challenges that remain, ShareVault, in partnership with Linda Pullan, PhD, of Pullan Consulting, has assembled a panel of six industry experts to discuss what’s already in the market, what’s in the clinic, and what we can expect to see in the future. Today, it appears that bsAbs are poised to be the next wave of antibody-based therapies for cancer and inflammatory disease. This has revolutionized the development of bsAb for therapeutic and diagnostic applications, enabling researchers to adjust the size, valency, flexibility, half-life, and biodistribution of bsAb to fit the desired target–product profile. Over the past two decades, protein and gene engineering has resulted in a range of recombinant bispecific antibody formats, with over 50 different formats now available. But we also use the term bispecifics for multi-target proteins that are not immunoglobulins. BsAbs can also place targets into close proximity, either to support protein complex formation on one cell or to trigger contacts between cells. BsAbs with ‘two-target’ or ‘multi-target’ functionality can interfere with multiple surface receptors or ligands associated, for example, with cancer, proliferation or inflammatory processes. As their name implies, bispecific antibodies (bsAbs) combine target recognition of two (or more) different antigens or epitopes. The major clinical and commercial success with antibody therapeutics has fueled much interest in developing next-generation antibody drugs, including bispecific antibodies. Bispecific Antibodies: Are Two Really Better Than One? 25 January, 2020Īntibodies are a well-established and rapidly growing drug class with dozens of antibody-based products currently marketed for imaging or therapy in the US and in Europe. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |